These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 20600480)
1. A randomized, double-blind, controlled clinical trial to evaluate the efficacy and safety of CJ-50300, a newly developed cell culture-derived smallpox vaccine, in healthy volunteers. Jang HC; Kim CJ; Kim KH; Lee KH; Byun YH; Seong BL; Saletti G; Czerkinsky C; Park WB; Park SW; Kim HB; Kim NJ; Oh MD Vaccine; 2010 Aug; 28(36):5845-9. PubMed ID: 20600480 [TBL] [Abstract][Full Text] [Related]
2. An open-label, single arm, phase III clinical study to evaluate the efficacy and safety of CJ smallpox vaccine in previously vaccinated healthy adults. Kim NH; Kang YM; Kim G; Choe PG; Song JS; Lee KH; Seong BL; Park WB; Kim NJ; Oh MD Vaccine; 2013 Oct; 31(45):5239-42. PubMed ID: 24021303 [TBL] [Abstract][Full Text] [Related]
3. Freeze-dried live attenuated smallpox vaccine prepared in cell culture "LC16-KAKETSUKEN": Post-marketing surveillance study on safety and efficacy compliant with Good Clinical Practice. Nishiyama Y; Fujii T; Kanatani Y; Shinmura Y; Yokote H; Hashizume S Vaccine; 2015 Nov; 33(45):6120-7. PubMed ID: 26455406 [TBL] [Abstract][Full Text] [Related]
4. Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults. Frey SE; Newman FK; Kennedy JS; Ennis F; Abate G; Hoft DF; Monath TP Vaccine; 2009 Mar; 27(10):1637-44. PubMed ID: 19071184 [TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of new cell-cultured smallpox vaccine compared with calf-lymph derived vaccine: a blind, single-centre, randomised controlled trial. Greenberg RN; Kennedy JS; Clanton DJ; Plummer EA; Hague L; Cruz J; Ennis FA; Blackwelder WC; Hopkins RJ Lancet; 2005 Jan 29-Feb 4; 365(9457):398-409. PubMed ID: 15680454 [TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial. Jackson LA; Frey SE; El Sahly HM; Mulligan MJ; Winokur PL; Kotloff KL; Campbell JD; Atmar RL; Graham I; Anderson EJ; Anderson EL; Patel SM; Fields C; Keitel W; Rouphael N; Hill H; Goll JB Vaccine; 2017 Mar; 35(13):1675-1682. PubMed ID: 28256358 [TBL] [Abstract][Full Text] [Related]
12. Smallpox vaccine, ACAM2000: Sites and duration of viral shedding and effect of povidone iodine on scarification site shedding and immune response. Pittman PR; Garman PM; Kim SH; Schmader TJ; Nieding WJ; Pike JG; Knight R; Johnston SC; Huggins JW; Kortepeter MG; Korman L; Ranadive M; Quinn X; Meyers MS Vaccine; 2015 Jun; 33(26):2990-6. PubMed ID: 25930115 [TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE. von Krempelhuber A; Vollmar J; Pokorny R; Rapp P; Wulff N; Petzold B; Handley A; Mateo L; Siersbol H; Kollaritsch H; Chaplin P Vaccine; 2010 Feb; 28(5):1209-16. PubMed ID: 19944151 [TBL] [Abstract][Full Text] [Related]
14. Phase II randomized, double-blinded comparison of a single high dose (5×10(8) TCID50) of modified vaccinia Ankara compared to a standard dose (1×10(8) TCID50) in healthy vaccinia-naïve individuals. Frey SE; Winokur PL; Hill H; Goll JB; Chaplin P; Belshe RB Vaccine; 2014 May; 32(23):2732-9. PubMed ID: 24607004 [TBL] [Abstract][Full Text] [Related]
15. Clinical and immunological response to attenuated tissue-cultured smallpox vaccine LC16m8. Saito T; Fujii T; Kanatani Y; Saijo M; Morikawa S; Yokote H; Takeuchi T; Kuwabara N JAMA; 2009 Mar; 301(10):1025-33. PubMed ID: 19278946 [TBL] [Abstract][Full Text] [Related]
16. Detailed kinetics of immune responses to a new cell culture-derived smallpox vaccine in vaccinia-naïve adults. Kim SH; Choi SJ; Park WB; Kim HB; Kim NJ; Oh MD; Choe KW Vaccine; 2007 Aug; 25(33):6287-91. PubMed ID: 17597266 [TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vollmar J; Arndtz N; Eckl KM; Thomsen T; Petzold B; Mateo L; Schlereth B; Handley A; King L; Hülsemann V; Tzatzaris M; Merkl K; Wulff N; Chaplin P Vaccine; 2006 Mar; 24(12):2065-70. PubMed ID: 16337719 [TBL] [Abstract][Full Text] [Related]
18. Profiling of the antibody response to attenuated LC16m8 smallpox vaccine using protein array analysis. Eto A; Fujita M; Nishiyama Y; Saito T; Molina DM; Morikawa S; Saijo M; Shinmura Y; Kanatani Y Vaccine; 2019 Oct; 37(44):6588-6593. PubMed ID: 31540810 [TBL] [Abstract][Full Text] [Related]
19. Vaccination success rate and reaction profile with diluted and undiluted smallpox vaccine: a randomized controlled trial. Talbot TR; Stapleton JT; Brady RC; Winokur PL; Bernstein DI; Germanson T; Yoder SM; Rock MT; Crowe JE; Edwards KM JAMA; 2004 Sep; 292(10):1205-12. PubMed ID: 15353533 [TBL] [Abstract][Full Text] [Related]
20. Clinical responses to smallpox vaccine in vaccinia-naive and previously vaccinated populations: undiluted and diluted Lancy-Vaxina vaccine in a single-blind, randomized, prospective trial. Kim SH; Yeo SG; Jang HC; Park WB; Lee CS; Lee KD; Kim HB; Kim NJ; Kim YT; Jee Y; Cho H; Oh MD; Choe KW J Infect Dis; 2005 Sep; 192(6):1066-70. PubMed ID: 16107961 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]